 REDWOOD CITY, Calif., May 17, 2021 GLOBE NEWSWIRE -- Rezolute, Inc. Nasdaq: RZLT, a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance, today announced that management will present at the Oppenheimer Rare and Orphan Disease Summit. The presentation will be available on-demand starting at 8:00 AM ET on Friday, May 21, 2021. 